Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2012

View Archived Issues

Takeda Pharmaceutical offers overview of third quarter fiscal 2011

BiondVax's phase II flu vaccine trial meets primary safety endpoint

Debiopharm commences phase Ib expansion study of Debio-0932

Hanmi and AngioLab enter licensing agreement

Studies point to benefit of sonothrombolysis after stroke

New antiviral agents disclosed by Alla Chem

Alla Chem presents new androgen receptor antagonists

Latvian company patents novel agents for influenza

New protein kinase inhibitors synthesized by Chinese team

Trials indicate ipilimumab can be administered with cancer vaccines

Novel tissue engineering scaffolds tested in vivo

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Novartis to revise product information for Rasilez in the E.U.

GlaxoSmithKline provides regulatory update on Tykerb/Tyverb

NeuroPhage Pharmaceuticals receives funding from Michael J. Fox Foundation

GlaxoSmithKline receives CHMP opinion on Nimenrix

Collaborating Japanese universities identify new potential target for cancer therapy

Gilead Sciences reports on ELECTRON trial

New approval for Zelboraf

Dainippon Sumitomo seeks line extension for Amlodin in Japan

EMA committee recommends conditional approval of Pixuvri

TCG Lifesciences chooses preclinical development candidate

CHMP recommends approval of Byetta line extension

FDA approves first medical therapy for endogenous Cushing's syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...